NPA chair steps aside while wholesaler price hike claims investigated

Nitin Sodha is stepping aside as chair of the National Pharmacy Association (NPA) while a government watchdog investigates his company’s involvement in drug price hiking.

Nitin_Green.jpg
Nitin Sodha: I'm stepping aside with immediate effect so the NPA isn't distracted

Mr Sodha will hand over his chairman duties while “allegations of collusion against a company in which he owns shares, Lexon UK, are investigated by the Competition and Markets Authority (CMA)”, the NPA announced this afternoon (June 3).

NPA vice-chair Andrew Lane, owner of the AlChem Pharmacy Group and chair of Gloucestershire local pharmaceutical committee, will pick up the chairman duties “for the time being”, the NPA added.

NPA chief executive Mark Lyonette said: “The allegations against Lexon don’t relate to Nitin’s work at the NPA, yet he has made a decision to stand aside as chair in the best interests of the association and its members.”

Mr Sodha added: “I am stepping aside with immediate effect, so the NPA can remain focused on supporting its members and securing a sustainable future for independent pharmacies, rather than be distracted by continued questions about my position as chair.”

The allegations against Lexon

The government’s competition watchdog alleged last month that Lexon, along with manufacturers Alliance Pharmaceuticals, Focus Pharmaceuticals and Medreich, broke the law by agreeing not to compete in the supply of anti-nausea drug prochlorperazine.

Their alleged agreement not to compete for the supply of prescription-only prochlorperazine 3mg buccal tablets led to prices for the NHS rising 700% over four years, the CMA claimed.

The CMA’s findings are provisional, the watchdog added, and the companies have the opportunity to make representations before it reaches a final decision.

Mr Sodha stressed to C+D last year that he currently has limited involvement with the wholesaler, and attends “maybe four” meetings a year.

Sign in or register for free

Latest from News

All the headlines: Community pharmacy funding deal

 
• By 
 • comment

Find out everything you need to know about the government’s plans for community pharmacy – as outlined in this week’s long-awaited pharmacy funding deal.

Pharmacy stop-smoking service expands to ‘non-registered’ staff

 
• By 
 • comment

The new pharmacy contract has expanded who can deliver the smoking cessation service, as well as adding the provision of two drugs via PGDs.

Revealed: 2024/25 contract cash uplift already paid

 
• By 
 • comment

Following this week’s announcement of the long-awaited pharmacy funding deal, C+D has learned that contractors have already received the additional £106 million in retrospective funding for 2024/25.

More from Politics

New evidence Brexit caused UK medicines shortages

 
• By 
 • comment

A health and social care think tank has revealed that the “elevated and troubling level” of medicine shortages in the UK can be blamed on Brexit.

Risk pharmacies ‘deprioritised’ if GP role grows, report warns

 
• By 
 • comment

A Westminster think tank has said that the government’s proposed Neighbourhood Health Service, which plans to scale up general practice, could put community pharmacies at risk of being “deprioritised”.